Related Experiment Video
Updated: May 21, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
Switchable Enzyme-Regulated ECM-Integrin-Cholesterol Signaling Orchestrate PD-L1 Dual Destabilization for Boosting
Wenbo Yin1,2, Yue Wang3, Zonghang Liu4
1State Key Lab of Electroanalytical Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin, China.
None:
Although PD-1/PD-L1 blockade therapy has shown clinical success, its efficacy in solid tumors remains limited by the immunosuppressive tumor microenvironment. The tumor extracellular matrix (ECM), which forms a dense physical barrier and activates integrin-mediated mechanotransduction to upregulate PD-L1, while cholesterol-enriched membrane domains stabilize integrin clustering and PD-L1 localization, forming a self-reinforcing ECM-integrin-cholesterol signaling network that drives immune evasion. Here, we designed a switchable natural enzyme nanoplatform with dual safety locks, co-delivering papain and cholesterol synthesis inhibitor simvastatin to disrupt this network at multiple levels. Papain remains inactive during systemic circulation and intracellular trafficking, ensuring biosafety, but is selectively activated by tumor-released glutathione and boosted by localized photothermal heating to precisely degrade ECM, suppressing integrin signaling and PD-L1 transcription, while simvastatin-driven cholesterol depletion amplifies this effect by destabilizing integrin clusters and promoting PD-L1 degradation. Combined with phototherapy-induced immunogenic cell death, this strategy remodels ECM, enhances T cell infiltration, overcomes checkpoint blockade resistance, and eradicates advanced tumors (∼500 mm3).
More Related Videos
09:40Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes
Published on: September 28, 2018
10:18Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023